Fifty months follow-up in patients with locally advanced cervical carcinoma (LACC) treated with low dose bi-weekly (ldbw) gemcitabine and cisplatin plus concurrent accelerated radiotherapy (AR)
A. Álvarez, E. Mickiewicz(University of Chicago), V. Cuartero, J. Rodger(Instituto de Oncología de Rosario), Diana de la Fuente de Dios, Pablo Menéndez(Parque Tecnológico de la Salud), Stella Gianni, H. Porcella, A. Gandur Quiroga, Beat Roth(University Hospital of Bern), Gabriela Cinat(German Cancer Research Center)
Cited by 2
Related Papers
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial
|Journal of Clinical Oncology|2000|318